BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SVACS - ECPv6.15.1.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.siliconvalleyacs.org
X-WR-CALDESC:Events for SVACS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260422T150000
DTEND;TZID=America/Los_Angeles:20260422T160000
DTSTAMP:20260604T104633
CREATED:20260411T231020Z
LAST-MODIFIED:20260411T231020Z
UID:22622-1776870000-1776873600@www.siliconvalleyacs.org
SUMMARY:Quantum Dots: From Biology to Quantum Science (30th Annual Stauffer Lectureship\, Day 2 of 2)
DESCRIPTION:Prof. Moungi Bawendi\, MIT\nSponsored by Stanford Department of Chemistry\nApril 22nd\, 3:00-4:00 pm\, In-person\, Free\, Stanford University\, Sapp Center Auditorium (STLC111)\, Learn more\n\nUnderstanding the chemical properties and the fundamental optoelectronic behavior of colloidal quantum dots is a prerequisite to their varied applications. This talk will focus on two very different paths: the use of quantum dots in biological imaging\, and their prospect as quantum emitters\, to illustrate the potential\, the challenges\, and the solutions that emerge when working with hybrid systems at the nanoscale. \nAbout the Speaker\nProfessor Moungi Bawendi\, the Lester Wolfe Professor of Chemistry at MIT\, received his A.B. in 1982 from Harvard University and his Ph.D. in 1988 from The University of Chicago. This was followed by two years of postdoctoral research at Bell Laboratories\, working with Louis Brus\, where he began his studies on nanomaterials. Bawendi joined the faculty at MIT in 1990\, becoming Associate Professor in 1995 and Professor in 1996. \nProfessor Bawendi was one of the initial developers of the field of colloidal quantum dots. Driven by an interest in light-matter interactions\, he has followed an interdisciplinary research program that has probed the science and technology of chemically synthesized nanostructures. His work has advanced both fundamental studies as well as applications. His laboratory has demonstrated applications of nanomaterials for light emission\, photodetection\, spectral sensing\, solar energy harvesting\, and bio-imaging. His group has pioneered novel optical tools for the spectroscopy of single nanostructures. \nProfessor Bawendi’s studies have included: (1) the development of methods for synthesizing\, characterizing\, processing\, and assembling quantum dots\, magnetic nanoparticles\, J-aggregates\, and thin films of semiconducting perovskites\, (2) the study of the fundamental optical and magnetic properties of nanostructures using a variety of spectroscopic methods\, including the development of photon correlation tools to study single nanoscopic emitters and emitters of quantum ligtht\, (3) incorporating quantum dots\, magnetic particles\, J-aggregates\, and thin film materials into optical and opto-electronic device structures\, and (4) developing optical tools and probes\, both fluorescent as well as magnetic\, including nanoparticles and other contrast agents\, for biomedical imaging. \nProfessor Bawendi is a fellow of the American Association for the Advancement of Science\, a fellow of the American Academy of Arts and Sciences\, a fellow of the National Academy of Inventors\, a member of the US National Academy of Sciences\, and a member of the National Academy of Engineering. \nProfessor Bawendi is a co-laureate of the 2023 Nobel Prize in Chemistry.
URL:https://www.siliconvalleyacs.org/event/quantum-dots-from-biology-to-quantum-science-30th-annual-stauffer-lectureship-day-2-of-2/
LOCATION:In-person
CATEGORIES:Lecture
ATTACH;FMTTYPE=image/webp:https://www.siliconvalleyacs.org/wp-content/uploads/2026/04/Moungi-Bawendi-MIT-e1775948832682.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260608T170000
DTEND;TZID=America/Los_Angeles:20260608T190000
DTSTAMP:20260604T104633
CREATED:20260514T185859Z
LAST-MODIFIED:20260602T191937Z
UID:22751-1780938000-1780945200@www.siliconvalleyacs.org
SUMMARY:Reprogramming How We Interface with the Human Body:                           High-Resolution 3D Printing Can Make the Unmakeable
DESCRIPTION:Prof. Joseph M. DeSimone\, Departments of Radiology and Chemical Engineering\, Stanford University\nThe seminar on Monday\, June 8\, starts at 6:00 PM Pacific time.\nAn in-person networking hour on the Stanford campus precedes the live presentation from 5:00 – 6:00 PM.\nRegistration required for campus location or for Zoom link.  Registration deadline: Sunday\, June 7\, 1:00 PM. \n\nAbstract\nThroughout my career\, I’ve been guided by the belief that transformative advances in medicine don’t arise solely from new molecules\, but equally from rethinking how those molecules are formulated and delivered to the body. This mindset has led to a series of unconventional dosage and delivery innovations—from biodegradable drug-eluting stents (BVS\, Inc.\, acquired by Guidant and now part of Abbott; co-founded with Bob Langer)\, to precisely engineered microparticles for inhalation (Liquidia Technologies; NASDAQ: LQDA)\, to iontophoretic platforms for localized chemotherapy (Focal Medical; IND approved by the FDA\, with patients treated beginning March 2026)—each opening new therapeutic frontiers. \nToday\, advances in high-resolution 3D printing are enabling a new chapter in this journey: the ability to engineer the skin as a programmable biological interface. Using microscale additive manufacturing\, we can create intradermal delivery systems that precisely control where and how therapeutics are introduced\, while simultaneously enabling access to rich biological information through interstitial fluid. \nThis bi-directional paradigm—delivering therapies while sampling biology—opens a fundamentally new approach to medicine. By targeting the skin and its underlying lymphatic network\, we can more effectively engage the immune system\, access early disease signals\, and move beyond traditional blood-based diagnostics toward continuous\, minimally invasive liquid biopsy. \nImportantly\, this is not simply a new device or formulation—it represents a scalable platform. Rather than building a traditional therapeutic pipeline molecule by molecule\, these technologies enable a delivery-centric model that can be applied broadly across vaccines\, biologics\, and diagnostics. \nIn this talk\, I will outline how focusing on new dosage delivery forms and new devices for liquid biopsies—now powered by high-resolution 3D printing—is redefining our interface with the human body\, transforming both how we treat disease and how we measure health. \nSpeaker Background\nJoseph M. DeSimone \nSanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering \nDepartments of Radiology and Chemical Engineering \nDepartment of Chemistry (by Courtesy) \nDepartment of Materials Science & Engineering (by Courtesy) \nGraduate School of Business (by Courtesy) \nStanford University \nProf. DeSimone is widely known by the Bay Area polymer science community and the academic world\, and his background\, interests\, and accomplishments are extensive and wide-ranging\, and far too long to fit in this note. For further information\, please see Stanford links: \nStanford Profile: https://profiles.stanford.edu/joseph-desimone \nResearch Group Website: https://desimonegroup.stanford.edu
URL:https://www.siliconvalleyacs.org/event/reprogramming-how-we-interface-with-the-human-body-how-high-resolution-3d-printing-can-make-the-unmakeable/
LOCATION:Hybrid
CATEGORIES:Webinar,Lecture
ATTACH;FMTTYPE=application/pdf:https://www.siliconvalleyacs.org/wp-content/uploads/2026/05/DeSimone_8June26_JointGGPF-SVACS_FLYER.pdf
END:VEVENT
END:VCALENDAR